Beefed-up patient privacy protections in the recently enacted economic
stimulus package are expected to place significant new restrictions on
how some players in the pharmaceutical supply chain, including chain
drugstores and PBMs, gather and distribute prescribing information to
pharmaceutical firms for what critics claim is the purpose of marketing
This article reviews the medical privacy restrictions
included in the American Recovery and Reinvestment Act, which President
Obama signed into law on Feb. 17, 2009, and discusses the impact these
restrictions might have on pharmaceutical marketing.
Topic headings include:
Read this article now. It's FREE...
- Limits Placed on HIPAA Exclusions
- Could Curtail Marketing
- Critics Warn That Rx Data Are Still Accessible
- Ensuring That Privacy Doesn't Hamper HIT
Download PDF file